Brivanib Alaninate

Preferred Label : Brivanib Alaninate;

NCIt definition : The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.;

Alternative definition : NCI-GLOSS: A substance being studied in the treatment of cancer. Brivanib alaninate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.;

UNII : U2Y5OFN795;

InChIKey : LTEJRLHKIYCEOX-OCCSQVGLSA-N;

CAS number : 649735-63-7;

Molecule name : BMS 582664; BMS-582664;

Chemical formula : C22H24FN5O4;

Codes from synonyms : CDR0000600439;

Details

Origin ID

C53397;

UMLS CUI

C1948076;

Currated CISMeF NLP mapping
- brivanib alaninate [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- brivanib alaninate [MeSH concept]
Validated automatic mappings to NTBT
- brivanib [MeSH Supplementary Concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Vascular Endothelial Growth Factor Receptor 2 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients